 AUSTIN, Texas, Sept. 30, 2021 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present interim data on Rhenium-186 NanoLiposome 186RNL from its ReSPECTTM Phase 1 clinical trial in recurrent glioblastoma GBM at the 2021 Society for Neuro-Oncology SNO Annual Meeting and Education Day being held November 18-21, 2021 in Boston, Massachusetts. 